文献速递免疫规划

佐剂型B组链球菌疫苗在55至75岁老年人中的随机双盲安慰剂对照I期临床试验

A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75.
PubMed 文献 · Vaccine · 2026-09-18

该I期试验评估了含四种α样蛋白N端结构域的佐剂型GBS疫苗(GBS-AlpN)在60名健康成人和30名肥胖和/或2型糖尿病(O/D)的55至75岁成人中的安全性、耐受性和免疫原性。参与者接受三剂肌肉注射。主要报告轻度局部和全身不良事件,无相关严重不良事件。疫苗在第二剂后即诱导出强劲且持久的抗体反应,各亚组结果相当,支持进一步临床研究。

要点

  • GBS-AlpN疫苗在老年健康及O/D人群中总体安全,主要为轻度不良事件。
  • 第二剂后即诱导对所有四种AlpN抗原的血清转化,抗体反应强劲且持久。
  • 健康与O/D亚组间免疫原性结果相当,支持进一步研究。

核心结论

  • GBS-AlpN疫苗在55至75岁健康及O/D成人中安全性良好,可诱导强劲持久抗体反应。

研究设计与样本

  • 随机、双盲、安慰剂对照I期试验,纳入60名健康成人和30名肥胖和/或2型糖尿病成人,年龄55至75岁。
  • 参与者按48:12和24:6比例随机接受三剂GBS-AlpN或安慰剂,分别于第1天、第4周和第24周肌肉注射。

主要发现

  • 53名健康参与者和26名O/D参与者报告主要为轻度的征集性局部和全身不良事件。
  • 报告7例严重不良事件,均与疫苗无关(安慰剂组3例,活性组4例)。
  • 43名健康参与者和22名O/D参与者报告至少1例非征集性不良事件,无严重非征集性不良事件与疫苗相关。
  • 至第57天,除3名接受GBS-AlpN的参与者外,所有参与者对四种AlpN均发生血清转化。
  • 疫苗在第二剂后即诱导强劲持久抗体反应,亚组间结果相当。

临床怎么用

  • 提示GBS-AlpN疫苗在老年人群中有良好安全性和免疫原性,支持进一步开展临床试验以优化接种策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Group B Streptococcus (GBS) disease is an increasing medical burden in adults. The present phase 1 trial evaluated an adjuvanted GBS vaccine (GBS-AlpN) containing N-terminal domains of four alpha-like proteins (AlpNs) (Alp1N, Alp2/3 N, RibN and AlpCN) in 60 healthy adults and 30 with obesity and/or type 2 diabetes (O/D) aged 55 to 75 years of age. Participants received three intramuscular doses of GBS-AlpN or placebo (48:12 and 24:6) on Day 1, Week 4 and Week 24. Solicited local and systemic adverse events (AEs), unsolicited AEs, and serious AEs (SAEs) were collected. Geometric mean concentrations of antibodies to the four AlpN antigens, and seroconversion were determined. The median age was between 65 and 66 years with more females in the healthy groups and more males in the O/D groups. Mainly mild solicited local and systemic AEs were reported for 53 healthy and 26 O/D participants. Seven SAEs, all unrelated, were reported (three in the placebo group and four in the active groups). At least 1 unsolicited AE was reported by 43 healthy and 22 O/D participants. None of the severe unsolicited AEs were related. By Day 57 all participants except three, who received GBS-AlpN had seroconverted for all four AlpNs. The vaccine elicited robust and durable antibody responses, already after the second dose, with comparable results between subgroups. These findings support further clinical investigation for the optimal vaccination strategy to protect vulnerable older adults against GBS disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Oostvogels L, Alhatemi A, De Gussem S, et al. A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75. Vaccine. 2026. PMID: 42759245. doi:10.1016/j.vaccine.2026.129133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。